1 5
. 24 Thus, CMG2 could regulate angiogenesis by impacting 1 3 9 cell proliferation and/or cell migration. We have previously demonstrated that PA SSSR affects cell 1 4 0 migration, but not proliferation in HMVEC 1 , a primary endothelial cell type. Consistent with this 1 4 1 result, CMG2 knockdown did not significantly reduce HMVEC proliferation (Fig S2A-D) . Similar 1 4 2 results are obtained for TEM8 knockdown. We also observe no reduction in cell proliferation in 1 4 3 EA.hy926 endothelial cells (a fusion of human umbilical vein cells with lung carcinoma cells) 1 4 4 treated with PA SSSR under conditions that selectively target CMG2 ( Fig S4A) . Together, these 1 4 5 data suggest that CMG2 inhibition must impact angiogenesis by modulating endothelial cell 1 4 6 migration, rather than cell proliferation. 1 4 7
Investigation of possible ECM ligands for CMG2. 1 4 8
Our data support the idea that PA SSSR exerts its anti-angiogenic effects by competing 1 4 9 with interaction(s) between the CMG2 von Willebrand Factor A (vWA) 25, 2 6 domain (including the 1 5 0 metal ion-dependent adhesion site (MIDAS) 5, 27 and endogenous ligand(s). However, the 1 5 1 specific ligands that regulate angiogenesis by binding CMG2 remain unidentified, although 1 5 2 different possibilities have been proposed 2, 8 . ECM proteins are likely candidates because of 1 5 3 CMG2's homology with integrins 2 6 , modest available data showing CMG2 interaction with ECM 1 5 4 proteins 2 , and the observation that in individuals with hyaline fibromatosis syndrome (HFS), 1 5 5 CMG2 mutations in the VWA domain result in widespread accumulation and of extracellular 1 5 6 matrix (ECM) proteins 8 . To verify interaction of CMG2 with ECM proteins, we used ELISA to 1 5 7 measure CMG2 K d for a series of different ECM proteins (Table S1 ; Fig S3 A-D) . Interestingly, 1 5 8 each of the ECM proteins tested (Collagens I, VI, laminin and fibronectin) interacted with CMG2 1 5 9 with near-indistinguishable near-micromolar K d values (Table S1 ). Similar K d values for different 1 6 0 ECM proteins in these assays did not reflect artefacts in the binding assay, since both positive 1 6 1 and negative control assays (CMG2 + PA SSSR and CMG2 + PA SSSR in the presence of EDTA, 1 6 2 respectively) mirrored previously published K d values 1 8
. Previously published data on CMG2-1 6 3 matrix interactions used single-concentration assessment to conclude that CMG2 may bind 1 6 4 preferentially to collagens IV 2 or VI 8 , but did not measure relative CMG2 affinity for different 1 6 5 ECM proteins. Differences in protein preparation, matrix adhesion to wells, number of binding 1 6 6 sites per molecule, and incubation time are all factors which influence relative signal observed in 1 6 7 blot-and ELISA-based assays, our binding curves are not necessarily at odds with previously 1 6 8 reported results. Differences in protein preparation, matrix adhesion to wells, and number of 1 6 9 binding sites per molecule are all factors which influence relative signal observed in blot-and 1 7 0 ELISA-based assays, and our binding curves are not necessarily at odds with previously 1 7 1 reported results 2, 8 . In addition, as a strategy to correct for possible differences in binding 1 7 2 kinetics between ECM proteins, our ELISA data was quantified after fluorescence signal had 1 7 3 largely stopped changing. Our initial time points showed much higher fluorescent signal for Col-1 7 4 VI than other ECM proteins, consistent with the single-concentration observations reported by 1 7 5 the van der Goot lab 8 ;
h owever, the observed higher fluorescent signal was not indicative of 1 7 6 higher affinity. Similar affinity of CMG2 for the matrix proteins tested, as shown in Table S1 , 1 7 7
indicates that CMG2 may bind to multiple ECM ligands and/or ECM peptide fragments. Such 1 7 8 broad binding of ECM proteins also indicates that CMG2 could, like integrins, a significant role 1 7 9 in cell adhesion and motility through direct interactions with the extracellular matrix. 1 8 0 CMG2 and its role in cell adhesion and migration. 1 8 1
To provide evidence for the assertion that CMG2 could play a role in cell adhesion, we 1 8 2 performed ex vivo cell adhesion assays with EA.hy926 cells on plates coated with different 1 8 3
ECMs (Collagens I, IV, and VI, Human Fibronectin, . Treatment with PA SSSR at 1 8 4 concentrations identical to the CMG2 K d value (200pM) significantly reduced EA.hy926 cell 1 8 5 2 2 7 3C). Significantly, knockout cells showed complete abolition of chemotactic migration ( Fig 3E) 2 2 8 but only slight alteration of chemokinetic migration (P<0.001) ( Fig 3F) .
9
To confirm that the loss of chemotaxis in CMG2 KO cells was not a consequence of off 2 3 0 target CRISPR effects, we complemented the CMG2 mutation with a CMG2-clover expression 2 3 1 vector and found that CMG2 add-back restored EA.hy926 cell chemotaxis ( Fig 3D-E ). Hence, 2 3 2 CMG2 is a critical component of chemotactic sensing or response in these cells, and may play a 2 3 3 role in regulating endothelial cell chemotaxis in vivo. Of interest, CMG2 is required for 2 3 4 reorientation of the mitotic spindle in zebrafish embryos 29 suggesting that it might also play a 2 3 5 role in orienting the microtubule cytoskeleton in a chemotactic context. 2 3 6 CMG2 impacts developmental angiogenesis. 2 3 7
We next investigated the effect of CMG2 deletion on developmental angiogenesis. To do 2 3 8 so, we compared retinal vessel development between WT and CMG2-/-mouse. We found that 2 3 9 the total vascular area was similar between the two genotypes ( Fig. 4) . However, the vascular 2 4 0 growth pattern observed was different between knockout and WT mice, with knockout mice 2 4 1 having a more bush-like pattern versus the tree-like pattern observed in WT animals ( Fig. 4A ).
4 2
Careful quantitation showed that the total number of veins in the retina of WT and CMG2-/-mice 2 4 3 is similar ( Fig 4A-B ), but CMG2-/-mice have slightly fewer primary arteries ( Fig 4A, C) .
4 4
Importantly, CMG2-/-mice showed 2.5-fold more primary branches per artery than the WT cells 2 4 5 ( Fig 4A, D) . This difference in vessel patterning could be consistent with the loss of chemotactic 2 4 6 migration observed in knockout cells. We speculate that in the absence of CMG2, endothelial 2 4 7 cells effectively lose chemotactic signals (though haptotactic and other signals may be 2 4 8 retained), which reduces effective directional movement. This (hypothesized) weaker response 2 4 9 in CMG2-/-mice to a developmental angiogenic gradient would leave some areas of the retina 2 5 0 with poor perfusion. Angiogenic signals from these areas could then lead to additional branching 2 5 1 to alleviate hypoxia, resulting in a vasculature that remains functional, but is patterned 2 5 2 differently. 2 5 3 CMG2-mediated chemotaxis is sensitive to multiple growth factors.
5 4
We have demonstrated here that CMG2-deficient mice showed potent reduction in 2 5 5 corneal neovascularization induced by both bFGF and VEGF. To more fully elucidate CMG2's 2 5 6 angioenic response to bFGF and VEGF, we carried out experiments that measured endothelial 2 5 7 cell chemotactic migration in response to these two growth factor gradients respectively. 2 5 8 EA.hy926 cells display chemotactic migration towards FBS, bFGF and VEGF ( Fig S5) , and this 2 5 9 migration is significantly inhibited with 200pM of PA SSSR treatment (Fig 3F, S5 ). Cells treated 2 6 0 with PA SSSR showed significantly lower chemotaxis in FBS, bFGF, or VEGF gradient ( Fig 3F, 2 6 1 S5), further suggest that CMG2 plays a critical role in mediating chemotaxis towards multiple 2 6 2 growth factors that are in the serum. Together, these data suggest that CMG2 may act as a 2 6 3 central regulator for chemotaxis that is initiated by bFGF and VEGF. The mechanism of CMG2's 2 6 4 impact on both bFGF and VEGF induced chemotaxis will be important for developing new 2 6 5 efficacious therapies to treat pathological angiogenesis. It remains to be seen whether 2 6 6 interaction of CMG2 with growth factors receptors at the cell surface can be detected. at 37 o C in a humidified environment with 5% CO 2 until ready for passaging. EA.hy cell proliferation assay 2 7 5 15,000 EA.hy926 cells were seeded into each well in a 96 well plate and incubated for 1 2 7 6 h to attach. After cell attachment, media with treatments were added. Ethanol fixed cells were 2 7 7 used as negative control. After a 24 h incubation, 20 µL CellTiter-Blue Reagent (Promega) was 2 7 8 added to each well for 4 h. Fluorescence signal (Ex: 560nm / Em: 590nm) was measured using 2 7 9 a BioTek Synergy H2 plate reader. All readings were normalized to the non-treated control. 2 8 0 Cell ASIC migration assay 2 8 1
The assay protocol followed the CellASIC ONIX M04G-02 Microfluidic Gradient Plate 2 8 2 User Guide. All media put into the plate (excepting the cell suspension) was filtered through a 2 8 3 0.2 µm syringe filter. EA.hy cells (3 x 10 6 cells/mL) were loaded in and incubated overnight with 2 8 4 DMEM + 10% FBS under flow at 37 o C. Assays were then performed with a stable gradient of 2 8 5 DMEM + 0 -10% FBS with or without peptide treatment. Brightfield images at 10x magnification 2 8 6 were taken every 10 min over 12 h on an Olympus IX73 microscope and the ORCA-Flash4.0 2 8 7 camera (Hamamatsu). Individual cells were tracked with Image J manual tracking plugin. Data 2 8 8 was transferred into the ibidi Chemotaxis and Migration Tools 2.0. to export endpoint y 2 8 9 displacement and accumulated displacement. P-values were calculated using Student's t-test 2 9 0 and error bars are standard error of the mean (n=50). 2 9 1 CMG2 ECM ELISA 2 9 2 All steps were performed at room temperature unless otherwise indicated. For binding 2 9 3 assays, matrix protein (Rockland Immunochemicals, Corning, EMD Millipore) was adsorbed 2 9 4 onto 96-well polyethylene plates (Greiner) by incubating 2 ug/mL matrix protein in HBS with 2 2 9 5 mM Mg 2+ and Ca 2+ (Buffer A) in individual wells at 4° C overnight. Bacillus anthracis protective 2 9 6 antigen (PA) was treated similarly but was incubated at 1 μ M in the same buffer. After 2 9 7 incubation, wells were washed 3x with Buffer A and blocked with 5% BSA (GoldBio) in HBS with 2 9 8 2 mM Mg 2+ , 2 mM Ca 2+ , and 0.1% Tween-20 (Buffer B) for 1 hour. Blocking was followed by 3 2 9 9 washes with Buffer B, after which varying concentrations of a biotinylated CMG2-AviTag EA.hy 926 cells were grown in DMEM supplemented with 10% FBS. 20μg/mL collagen I, 3 1 0 IV, VI, laminin, fibronectin, PA SSSR , and BSA were preared in PBS and coated in 96well plate 3 1 1 (100 g/well) overnight at 4 o C. After coating, collagen I, IV, VI, laminin, fibronectin, PA SSSR , and 3 1 2 BSA were removed and 5% BSA were coated for 1 hour. Cells were deprived with serum by 3 1 3 scraped and cells were at 100g for 10 minutes and the supernatant was discarded. Cells then 3 1 4 resuspended at 2-3x10 5 cells/mL in DMEM. 100μL of cells were added to each of the coated 3 1 5 wells. The plate was incubated at 37 o C for 1 hour to allow the cells to adhere on the surface. 3 1 6
Each well was washed gently for two times using warm serum-free DMEM by multi-channel 3 1 7 pipettor. 100μL of serum free DMEM and 20μL of cell-titler blue (Promega Cat#G8080) were 3 1 8 added into each well, and incubated for 4 hours at 37 o C. After 4 hours incubation, fluorescent 3 1 9 signal of 96 well plate was measured at 560 Ex /590 Em by a plate reader. 3 2 0
EAhy 926 CMG2 KO development: 3 2 1 HEK 293T cells (3.8 x 10 6 cells) were seeded in 10cm tissue culture dish for 18 hours. 3 2 2 12μg of pCMV, 5μg of pVSVG, 12.5μg of Lenti-CRISPR (targeting CMG2 exon 1, sgRNA 3 2 3 sequence: GCACCAACAGCCACAGCCCG), 90μL of 1mg/mL PEI and 600μL of serum-free 3 2 4 DMEM were mixed into a tube and incubated for 15 minutes before adding to the 10cm culture 3 2 5 dish. The dish was replaced with 10mL of 10% FBS DMEM in 4 hours and followed by 48 hours 3 2 6 incubation. Media was removed from the transfected cells into a conical tube, and was spin at 3 2 7 2500g for 3 minutes to remove debris. The supernatant (lentivirus) and 10μg/mL polybrene were 3 2 8 added to 40% confluent EA.hy926 cells and incubated for 24 hours. The next day, media was 3 2 9 removed, fresh 10% FBS DMEM and 1μg/mL puromycin were added to the plate for 3-5 days. 3 3 0
After 3-5 days, the cells that survived in the selection were diluted into single colony in 96 well 3 3 1 plate. 3 3 2 PA uptake flow cytometry: 3 3 3 CMG2 KO EA.hy 926 cells and WT EA.hy926 cells were split in 12 well plate at 50% 3 3 4 confluent. 200pM PA-Alexa Fluor 546 was added into each well and incubated overnight. Then 3 3 5 cells were trypsinized and resuspended into a microcentrifuge tube. Cells were washed once 3 3 6 with complete media. Then 50,000 cells of each condition were sent to Cytoflex (RIC facility at 3 3 7 BYU). Data was collected and analyzed in our lab by using FlowJo software. 3 3 8
Corneal micropocket assay 3 3 9
The corneal micropocket assay was performed as described 16 using pellets containing 80 ng 3 4 0 of basic fibroblast growth factor (bFGF) or 180 ng of human carrier-free recombinant vascular 3 4 1 endothelial growth factor (VEGF; R&D Systems) in C57BL/6J mice. The treated groups received 3 4 2 daily or twice daily i.p injections for 5 (bFGF) or 6 (VEGF) consecutive days of protein in PBS. Chemical). Cells (10,000 per well) were plated onto wells containing medium alone or medium 3 6 1
containing the molecule to be tested. These wells were suspended above wells containing 5 to 10 3 6 2 ng/mL recombinant human VEGF (R&D Systems) or full serum medium. Cells were allowed to 3 6 3 migrate for 4 h. Membranes were rinsed once in PBS and then fixed and processed using Diff-Quick 3 6 4 (Dade Diagnostics). Cells on the top of the membrane were removed using cotton-tipped 3 6 5 applicators, and the membrane was removed from the insert using a scalpel. Membranes were then 3 6 6 mounted on slides, and the number of cells in a microscopic field was counted manually.
6 7
HMVEC CMG2 / TEM8 KD 3 6 8 CMG2 and/or TEM8 knockdown in HMVEC was achieved using Dharmacon smartpools 3 6 9 (Dharmacon, Lafayette, CO) and RNAimax (ThermoFisher, Waltham, MA) in OPTI-MEM with 3 7 0
Glutamax (ThermoFisher, Waltham, MA). Approximately 6 hours after addition of the 3 7 1 transfection complex, an equal volume of EBM-2 was added to the cells, and media was 3 7 2 changed to EBM-2 ~18 hours later. 3 7 3 HMVEC tube formation assay 3 7 4
Human microvascular endothelial cells were maintained as above. Before the assay, a 1-to 3 7 5 2-mm layer of Matrigel was plated into the wells of a 12-well cluster. Approximately 10 5 cells were 3 7 6 plated on this layer in EGM-2. Plates were examined at 12, 14, 16, 18, and 24 h for differences in 3 7 7 network formation. In each experiment, good network formation was observed in untreated control 3 7 8 wells.
7 9
CMG2 and TEM8 KO mice 3 8 0 CMG2 and TEM8 knockout mice were a kind gift from Stephen Leppla. They were housed in 3 8 1 the ARCH facility at Boston Children's Hospital on standard food and bedding (CMG2) or on 3 8 2 standard food and bedding, with supplemental soft food available (Nutra-gel mouse diet, Bio-3 8 3
Serv, Flemington, NJ). Genotyping was performed by Transnetyx (Cordova, TN). 3 8 4
Western Blotting 3 8 5
Near-confluent HMVEC WT and CMG2 / TEM8 KD cells were washed three times in cold PBS, and 3 8 6 lysed for 30min at 4 o C in PBS supplemented with 1% Triton X-100 and a protease inhibitor cocktail 3 8 7 (cOmplete mini protease inhibitor cocktail, Roche). Lysates were cleared by centrifugation at 16,000 xg and the supernatant protein concentration was measured by BCA assay. Protein (40μg) from 3 8 9 each sample was used for SDS-PAGE and blotted onto PVDF. Following blocking, the membranes 3 9 0 were probed with antibodies against CMG2 (1:1000 16723-1-AP, Proteintech, Rosemont, IL) or 3 9 1 TEM8 (1:1000 ab21269, Abcam, Cambridge, UK), then stripped and reprobed for beta-actin 3 9 2
(1:10,000 A5441, Sigma) as loading control. Blots were imaged using a ChemiDoc imager (Bio-3 9 3
Rad, Hercules, CA). were also assayed for binding, but curves are not displayed due to poor fit. In each case, similar 4 8 8
binding affinites (500 nM-1 uM) were observed (see Supplementary Table S1 ). respectively). Each migration condition were performed 37 o C for 8 hours. Cell tracking was done 5 0 9
in ImageJ with forty cells were tracked in each condition. Raw data were then imported into 5 1 0 chemotaxis and migration tool from ibidi to make track plots. 
